The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Learn about estimated costs for the drug sofosbuvir (brand name Sovaldi) that will help treat patients with Hepatitis C. Gregg Alton, a vice president at Gilead, comments that, "Gilead will help U.S. patients pay for sofosbuvir if they can't afford it...or the company will help them look for drug coverage."
Continue reading »
With the approval of Sovaldi™ (sofosbuvir) once a day combination treatment of those with Hepatitis C, genotype 1, 2, 3 and 4, many questions arise. Here we have summarized some of these questions.
Continue reading »Learn about the positive results from phase 2 trials of adding danoprevir to the current treatment regimen (peginterferon alfa-2a/ribavirin) for Hepatitis C.
Continue reading »Find out about Sovaldi (sofosbuvir), the second drug the FDA has approved since the end of November for the treatment of Hepatitis C.
Continue reading »Find out about AbbVie Inc. and its progress in developing an oral treatment for Hepatitis C.
Continue reading »Learn more about samatasvir, simeprevir and TMC647055 – all of which are being tested for an all-oral, direct-acting antiviral (DAA) HCV combination therapy.
Continue reading »By way of protein analysis, scientists at The Scripps Research Institute (TSRI) are forging ahead in the race to create a Hepatitis C vaccine.
Continue reading »Janssen Therapeutics' OLYSIO™ (simeprevir) has been approved by the FDA. It is a prescription medicine used with other antiviral medicines to treat genotype 1 chronic hepatitis C in adults. Learn more about how OLYSIO™ works.
Continue reading »A Phase 2b trial of ABT-450 (a once-a-day, all-oral drug regimen) revealed an average sustained virologic response of 95 percent in newly-diagnosed patients.
Continue reading »Learn more about Merck's investigational, all-oral combination regimen for Hepatitis C, MK-5172/MK-8742, that recently received Breakthrough Therapy designation by the FDA.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
